In particular, similar DFS rates were observed between HER2-0 and HER2-low-positive BC cohorts (HR 0.79, 95% CI 0.51–1.21, p = 0.27 log-rank test and Cox-regression model; Supplementary Fig. 1A). This evidence concerns the gene ERBB2 and breast cancer.